Physician profile
John Pybass
NPI 1891913455
$2,285.57
in general payments reported to CMS, 2019-2025
17 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.16 · 2020: $17.57 · 2021: $431 · 2022: $492 · 2023: $673 · 2024: $488 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $486.64 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $434.64 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $422.91 | 2021-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $211.75 | 2020-2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $137.31 | 2021-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $102.64 | 2019-2021 | |
| Lundbeck LLC | $93.39 | 2022-2024 | Rexulti |
| Axsome Therapeutics, INC. | $70.96 | 2023 | Auvelity |
| Almatica Pharma LLC | $70.45 | 2024 | Loreev Xr |
| Bausch Health US, LLC | $60.74 | 2022-2024 | Aplenzin, Wellbutrin |
| Novo Nordisk INC | $54.14 | 2025 | Wegovy |
| Currax Pharmaceuticals LLC | $31.99 | 2023 | Contrave |
| Sanofi-Aventis U.S. LLC | $24.93 | 2025 | |
| Alkermes, INC. | $23.91 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $21.49 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $19.38 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pybass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.